Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.

Abstract

BackgroundBiomarkers are used for diagnosis, risk stratification and medical decisions. Copeptin and mid‐regional proadrenomedullin (MR‐proADM) are markers of stress and endothelial function, respectively, which have been studied in pneumonia, sepsis and septic shock. This study aimed to assess whether copeptin and MR‐proADM could predict coronavirus disease 2019 (COVID‐19) in‐hospital outcomes, that is multi‐system complications, length of stay and mortality.MethodsCopeptin and MR‐proADM were assessed at admission in 116 patients hospitalized with COVID‐19. Data were retrospectively extracted from an online database. The primary endpoint was in‐hospital mortality. The secondary endpoints were in‐hospital complications, the composite outcome ‘death, or admission to intensive care unit, or in‐hospital complications’, and length of stay. The predictive power was expressed as area under the receiver operator characteristic curve (AUROC).ResultsCopeptin was increased in non‐survivors (median 29.7 [interquartile range 13.0–106.2] pmol/L) compared to survivors (10.9 [5.9–25.3] pmol/L, p < 0.01). The AUROC for mortality was 0.71, with a hazard ratio of 3.67 (p < 0.01) for copeptin values > 25.3 pmol/L. MR‐proADM differentiated survivors (0.8 [0.6–1.1] nmol/L) from non‐survivors (1.5 [1.1–2.8] nmol/L, p < 0.001) and yielded a AUROC of 0.79 and a hazard ratio of 7.02 (p < 0.001) for MR‐proADM values > 1.0 nmol/L. Copeptin and MR‐proADM predicted sepsis (AUROC 0.95 and 0.96 respectively), acute kidney injury (0.87 and 0.90), the composite outcome (0.69 and 0.75) and length of stay (r = 0.42, p < 0.001, and r = 0.46, p < 0.001).ConclusionsAdmission MR‐proADM and copeptin may be implemented for early risk stratification in COVID‐19‐hospitalized patients to help identify those eligible for closer monitoring and care intensification.